Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhe Sheng

Showing results (371-380 of 669) with videos related to

Pageof 67
Sort By:
International Journal of Biological Sciences|July 30, 2021
The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug ResistanceSilpa Narayanan, Zhuo-Xun Wu, Jing-Quan Wang, et al.
Oncology Reports|March 26, 2013
Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10)Wen Deng, Chun-Ling Dai, Jun-Jiang Chen, et al.
Frontiers in Pharmacology|December 13, 2023
Protective effects of Salvianic acid A against multiple-organ ischemia-reperfusion injury: a reviewShiyu Yang, Heming Chen, Wei Su, et al.
Signal Transduction and Targeted Therapy|March 11, 2023
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategiesZhen-Duo Shi, Kun Pang, Zhuo-Xun Wu, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|September 4, 2021
Novel nanomedicines to overcome cancer multidrug resistanceZhenwei Su, Shaowei Dong, Shan-Chao Zhao, et al.
Frontiers in Oncology|October 5, 2020
Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling PathwayXiaozhong Liao, Lanting Tao, Wei Guo, et al.
Acta Pharmaceutica Sinica. B|June 1, 2022
MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: <i>In vitro</i> and <i>in vivo</i> studyZhuo-Xun Wu, Qiu-Xu Teng, Yuqi Yang, et al.
European Journal of Medicinal Chemistry|February 5, 2022
Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridoninJunkai Liu, Shaowen Xie, Xiao Shao, et al.
Frontiers in Pharmacology|January 29, 2019
Y<sub>6</sub>, an Epigallocatechin Gallate Derivative, Reverses ABCG2-Mediated Mitoxantrone ResistanceRui-Qiang Zhao, Yan Wen, Pranav Gupta, et al.
International Journal of Molecular Sciences|March 6, 2021
The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 TransporterSilpa Narayanan, Nehaben A Gujarati, Jing-Quan Wang, et al.
Pageof 67

Showing results (371-380 of 669) with videos related to

Sort By:
Pageof 67
International Journal of Biological Sciences|July 30, 2021
The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug ResistanceSilpa Narayanan, Zhuo-Xun Wu, Jing-Quan Wang, et al.
Oncology Reports|March 26, 2013
Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10)Wen Deng, Chun-Ling Dai, Jun-Jiang Chen, et al.
Frontiers in Pharmacology|December 13, 2023
Protective effects of Salvianic acid A against multiple-organ ischemia-reperfusion injury: a reviewShiyu Yang, Heming Chen, Wei Su, et al.
Signal Transduction and Targeted Therapy|March 11, 2023
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategiesZhen-Duo Shi, Kun Pang, Zhuo-Xun Wu, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|September 4, 2021
Novel nanomedicines to overcome cancer multidrug resistanceZhenwei Su, Shaowei Dong, Shan-Chao Zhao, et al.
Frontiers in Oncology|October 5, 2020
Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling PathwayXiaozhong Liao, Lanting Tao, Wei Guo, et al.
Acta Pharmaceutica Sinica. B|June 1, 2022
MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: <i>In vitro</i> and <i>in vivo</i> studyZhuo-Xun Wu, Qiu-Xu Teng, Yuqi Yang, et al.
European Journal of Medicinal Chemistry|February 5, 2022
Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridoninJunkai Liu, Shaowen Xie, Xiao Shao, et al.
Frontiers in Pharmacology|January 29, 2019
Y<sub>6</sub>, an Epigallocatechin Gallate Derivative, Reverses ABCG2-Mediated Mitoxantrone ResistanceRui-Qiang Zhao, Yan Wen, Pranav Gupta, et al.
International Journal of Molecular Sciences|March 6, 2021
The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 TransporterSilpa Narayanan, Nehaben A Gujarati, Jing-Quan Wang, et al.
Pageof 67